<DOC>
	<DOCNO>NCT00531427</DOCNO>
	<brief_summary>The objective study determine analgesic efficacy safety Buprenorphine Transdermal System ( BTDS ) 10 20 compare placebo opioid-na√Øve subject moderate severe chronic pain due osteoarthritis ( OA ) knee . The double-blind treatment intervention duration 12 week , time supplemental analgesic medication ( immediate-release oxycodone first 6 day postrandomization acetaminophen ibuprofen remainder double-blind phase ) provide subject addition study drug .</brief_summary>
	<brief_title>Buprenorphine Transdermal System ( BTDS ) Subjects w/Mod-sev Osteoarthritis ( OA ) Chronic Pain Knee</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic setting relief moderate severe pain . BTDS transdermal system formulation design deliver consistent steady dose buprenorphine 7-day period limit blood concentration fluctuation .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>subject moderate severe chronic osteoarthritis ( OA ) pain knee ( lasting several hour daily ) predominant pain condition , clinical diagnosis OA knee 1 year longer , subject treat within 14 day prior screen nonopioid therapy , therapy include opioids dose &lt; 5 mg oxycodone ( equivalent ) per day , subject whose OA knee pain adequately control nonopioid analgesic medication investigator feel appropriate candidate aroundtheclock opioid therapy . subject arthroscopy either knee hip within 6 month enter study open surgery either knee hip within 9 month enter study , subject allergic buprenorphine history allergy opioids , subject allergies contraindication transdermal delivery system patch adhesive . Other protocolspecific inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Chronic pain ,</keyword>
	<keyword>OA knee ,</keyword>
	<keyword>opioid ,</keyword>
	<keyword>transdermal</keyword>
</DOC>